Enovis CorporationENOV stock score: 47/100
$26.23 · -3.21% · Scored Nov 19, 2026
- Technical
- 45
- Fundamental
- 47
- News
- 53
The reading
Enovis (ENOV) scores 47 out of 100, which reads weak, higher than 39% of Healthcare stocks and 37% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 47, technicals 45.
Among the fundamentals, Price Target at 100 and Earnings Growth (Quarterly) at 99 score highest, while Earnings Quality (Yearly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 62 and contrarian oscillators 39.
News sentiment is neutral at 53; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 31 to 48, and it is up 7 points over the period.
About Enovis
Enovis (ENOV) is a U.S. medical technology company focused on orthopedics. Its Reconstructive segment makes implants for hip, knee, shoulder and foot and ankle joint replacement, along with surgical instruments and related technology, and it expanded internationally by acquiring Lima Corporate of Italy. Its Prevention and Recovery segment, built on the former DJO business, makes orthopedic bracing and supports, cold therapy and bone growth stimulation devices, rehabilitation equipment and other products used to prevent injuries and help patients recover after surgery or injury. Enovis has sold its Dr. Comfort diabetic footwear business to sharpen its focus. Customers include orthopedic surgeons, hospitals, ambulatory surgery centers, physical therapists, clinics and patients, served through direct sales teams and distributors around the world. Enovis earns money from selling implants, devices and equipment, with reimbursement coming largely from public and private insurers.
In joint replacement, Enovis competes with Stryker, Zimmer Biomet and Smith+Nephew, and in bracing and recovery with companies such as Breg. Its edge rests on an established shoulder replacement franchise, a broad bracing and recovery portfolio sold through a large network of clinicians and the ability to offer care across the course of treatment. Investors who follow ENOV stock tend to watch organic revenue growth in each segment and new implant launches. Adjusted margins and cost savings are closely followed. Integration of Lima, reimbursement changes, debt levels and portfolio moves are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ENOV’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
47Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Forward P/E ratio uses estimated future earnings to calculate valuation.
Holding it back
How reliably yearly earnings grow: the share of years with higher earnings, the compound growth rate, how steady that growth is, and the last two yearly changes.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
60Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- VWAP100
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
- SMA 50100
Simple Moving Average (50-period) is a widely-watched intermediate-term trend gauge.
Holding it back
Annualised volatility of the last 60 daily returns.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
- SMA 1013
Simple Moving Average (10-period) smooths price action over 10 periods.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 53
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 34 | 1 |
| Daily | 60 | 3 |
| Weekly | 47 | 2 |
| Monthly | 32 | 2 |
| Quarterly | 37 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 47 |
| Nov 18, 2026 | 47 |
| Nov 17, 2026 | 47 |
| Nov 16, 2026 | 48 |
| Nov 15, 2026 | 47 |
| Nov 14, 2026 | 48 |
| Nov 13, 2026 | 47 |
| Nov 12, 2026 | 46 |
| Nov 11, 2026 | 45 |
| Nov 10, 2026 | 45 |
| Nov 8, 2026 | 43 |
| Nov 7, 2026 | 43 |
| Nov 6, 2026 | 43 |
| Nov 5, 2026 | 43 |
| Nov 4, 2026 | 42 |
| Nov 3, 2026 | 36 |
| Nov 2, 2026 | 37 |
| Nov 1, 2026 | 36 |
| Oct 30, 2026 | 36 |
| Oct 29, 2026 | 40 |
| Oct 28, 2026 | 39 |
| Oct 27, 2026 | 38 |
| Oct 26, 2026 | 37 |
| Oct 25, 2026 | 38 |
| Oct 24, 2026 | 38 |
| Oct 23, 2026 | 38 |
| Oct 22, 2026 | 39 |
| Oct 21, 2026 | 38 |
| Oct 20, 2026 | 38 |
| Oct 19, 2026 | 38 |
| Oct 18, 2026 | 37 |
| Oct 17, 2026 | 36 |
| Oct 16, 2026 | 37 |
| Oct 15, 2026 | 36 |
| Oct 14, 2026 | 35 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 35 |
| Oct 11, 2026 | 34 |
| Oct 10, 2026 | 34 |
| Oct 9, 2026 | 34 |
| Oct 8, 2026 | 33 |
| Oct 7, 2026 | 33 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 35 |
| Oct 4, 2026 | 33 |
| Oct 3, 2026 | 33 |
| Oct 2, 2026 | 33 |
| Oct 1, 2026 | 33 |
| Sep 30, 2026 | 34 |
| Sep 29, 2026 | 35 |
| Sep 28, 2026 | 33 |
| Sep 27, 2026 | 35 |
| Sep 26, 2026 | 35 |
| Sep 25, 2026 | 35 |
| Sep 24, 2026 | 34 |
| Sep 23, 2026 | 35 |
| Sep 22, 2026 | 34 |
| Sep 21, 2026 | 33 |
| Sep 20, 2026 | 33 |
| Sep 19, 2026 | 33 |
| Sep 18, 2026 | 33 |
| Sep 17, 2026 | 33 |
| Sep 16, 2026 | 32 |
| Sep 15, 2026 | 32 |
| Sep 14, 2026 | 32 |
| Sep 13, 2026 | 34 |
| Sep 12, 2026 | 34 |
| Sep 11, 2026 | 34 |
| Sep 10, 2026 | 32 |
| Sep 9, 2026 | 33 |
| Sep 8, 2026 | 34 |
| Sep 7, 2026 | 32 |
| Sep 6, 2026 | 32 |
| Sep 5, 2026 | 33 |
| Sep 4, 2026 | 31 |
| Sep 3, 2026 | 32 |
| Sep 2, 2026 | 33 |
| Sep 1, 2026 | 33 |
| Aug 31, 2026 | 35 |
| Aug 30, 2026 | 38 |
| Aug 29, 2026 | 38 |
| Aug 28, 2026 | 38 |
| Aug 27, 2026 | 36 |
| Aug 26, 2026 | 38 |
| Aug 25, 2026 | 39 |
| Aug 24, 2026 | 39 |
| Aug 23, 2026 | 40 |
| Aug 22, 2026 | 40 |
Key facts
- Market cap
- $1.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 1.42
- Risk grade (1–10)
- 1
- Next earnings
- Nov 5, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| INSP Inspire Medical Systems | $1.6B | 60 |
| BFLY Butterfly Network | $1.6B | 47 |
| PRCT PROCEPT BioRobotics | $1.5B | 51 |
| CNMD CONMED | $1.4B | 57 |
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
Questions
What is ENOV's stock rating today?
ENOV scores 47/100 (Weak) as of Nov 19, 2026: technical 45, fundamental 47, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.
What does Enovis do?
Enovis (ENOV) is a U.S. medical technology company focused on orthopedics.
Is ENOV stock a buy?
The score is not a buy or sell recommendation. A 47 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ENOV score calculated?
99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/enov/"><img src="https://stocksscores.com/stocks/enov/badge.svg" alt="ENOV stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/enov/)